EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Circulating Tumor DNA Predicts Early Recurrence Following Locoregional Therapy for Oligometastatic Colorectal Cancer

Conor D J O'Donnell iD, Nikolas Naleid, Teerada Siripoon iD, Kevin G Zablonski iD, Michael H Storandt iD, Jennifer E Selfridge, Christopher L Hallemeier, Madison L Conces, Krishan R Jethwa, David L Bajor, Cornelius A Thiels, Susanne G Warner und 5 weitere

Cancers · 29.06.2024 · 16 (13) · 2407

DOI: 10.3390/cancers16132407 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 29.06.2024. Verfasst von Conor D J O'Donnell und 16 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic School of Graduate Education, Mayo Clinic College of Medicine, Mayo Building, Rochester, MN 55905, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

(1)

Background

Local therapies offer a potentially curative approach for patients with oligometastatic colorectal cancer (CRC). An evidence-based consensus recommendation for systemic therapy following definitive locoregional therapy is lacking. Tumor-informed circulating tumor DNA (ctDNA) might provide information to help guide management in this setting. (2)

Methods

A multi-institutional retrospective study was conducted, including patients with CRC that underwent curative-intent locoregional therapy to an isolated site of metastatic disease, followed by tumor-informed ctDNA assessment. The Kaplan–Meier method and log-rank tests were used to compare disease-free survival based on ctDNA results. ctDNA test performance was compared to carcinoembryonic antigen (CEA) test results using McNemar’s test. (3)

Results

Our study cohort consisted of 87 patients treated with locoregional interventions who underwent ctDNA testing. The initial ctDNA test post-intervention was positive in 28 patients and negative in 59 patients. The median follow-up time was 14.0 months. Detectable ctDNA post-intervention was significantly associated with early disease recurrence, with a median disease-free survival (DFS) of 6.63 months compared to 21.30 months in ctDNA-negative patients (p < 0.001). ctDNA detected a numerically higher proportion of recurrences than CEA (p < 0.097). Post-intervention systemic therapy was not associated with improved DFS (p = 0.745). (4) Conclusions: ctDNA results are prognostically important in oligometastatic CRC, and further prospective studies are urgently needed to define its role in guiding clinical decisions.

Schlagwörter

Stichwörter der Autor:innen

ablationchemotherapycirculating tumor DNAcolorectal cancerhepatectomyoligometastatic diseasestereotactic body radiation therapy

Autor:innen und Institutionen

  • Mayo Clinic School of Graduate Education, Mayo Clinic College of Medicine, Mayo Building, Rochester, MN 55905, USA.
  • Department of Medicine, University Hospitals of Cleveland, Lakeside Building, 11100 Euclid Avenue, Cleveland, OH 44016, USA.
  • Division of Medical Oncology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand.
  • University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA.
  • Department of Radiation Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
  • Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.

ORCID-Profile: Conor D J O'Donnell, Teerada Siripoon, Kevin G Zablonski, Michael H Storandt, Patrick P Starlinger, Jessica L Mitchell, Amit Mahipal, Zhaohui Jin

Zitieren

APA

O'Donnell, C. D. J., Naleid, N., Siripoon, T., Zablonski, K. G., Storandt, M. H., Selfridge, J. E., Hallemeier, C. L., Conces, M. L., Jethwa, K. R., Bajor, D. L., Thiels, C. A., Warner, S. G., Starlinger, P. P., Atwell, T. D., Mitchell, J. L., Mahipal, A., & Jin, Z. (2024). Circulating Tumor DNA Predicts Early Recurrence Following Locoregional Therapy for Oligometastatic Colorectal Cancer. Cancers, 16(13), 2407. https://doi.org/10.3390/cancers16132407

Vancouver

O'Donnell CDJ, Naleid N, Siripoon T, Zablonski KG, Storandt MH, Selfridge JE, et al. Circulating Tumor DNA Predicts Early Recurrence Following Locoregional Therapy for Oligometastatic Colorectal Cancer. Cancers. 2024;16(13):2407. doi:10.3390/cancers16132407

BibTeX
@article{ODonnell2024,
  author = {O'Donnell, Conor D J and Naleid, Nikolas and Siripoon, Teerada and Zablonski, Kevin G and Storandt, Michael H and Selfridge, Jennifer E and Hallemeier, Christopher L and Conces, Madison L and Jethwa, Krishan R and Bajor, David L and Thiels, Cornelius A and Warner, Susanne G and Starlinger, Patrick P and Atwell, Thomas D and Mitchell, Jessica L and Mahipal, Amit and Jin, Zhaohui},
  title = {Circulating Tumor DNA Predicts Early Recurrence Following Locoregional Therapy for Oligometastatic Colorectal Cancer},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {13},
  pages = {2407},
  doi = {10.3390/cancers16132407}
}
Kostenlos starten →